Market capitalization | $476.20m |
Enterprise Value | $213.44m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.47 |
P/S ratio (TTM) P/S ratio | 3.27 |
P/B ratio (TTM) P/B ratio | 1.82 |
Revenue growth (TTM) Revenue growth | -50.30% |
Revenue (TTM) Revenue | $145.60m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
11 Analysts have issued a Arcturus Therapeutics Ltd forecast:
11 Analysts have issued a Arcturus Therapeutics Ltd forecast:
Sep '24 |
+/-
%
|
||
Revenue | 146 146 |
50%
50%
|
|
Gross Profit | 142 142 |
-
|
|
EBITDA | -27 -27 |
121%
121%
|
EBIT (Operating Income) EBIT | -30 -30 |
124%
124%
|
Net Profit | -60 -60 |
160%
160%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Head office | Israel |
CEO | Joseph Payne |
Employees | 180 |
Founded | 2013 |
Website | www.arcturusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.